Rapid Advances in Litifilimab: Insights from LILAC to AMETHYST in CLE
Insights from the Phase 2 LILAC Study on Litifilimab in Cutaneous Lupus Erythematosus
Dr. Victoria Werth, a distinguished Professor of Dermatology and Medicine at the University of Pennsylvania, as well as the Chief of Dermatology at the Philadelphia VA Medical Center, recently shared pivotal findings from the phase 2 LILAC study regarding the use of litifilimab in treating cutaneous lupus erythematosus (CLE). Additionally, she elaborated on the rationale behind the ongoing phase 3 AMETHYST program and the broader significance of the recent FDA Breakthrough Therapy Designation awarded to this treatment.
Outcomes from the LILAC Trial
The results from the LILAC trial, which were published in The New England Journal of Medicine, specifically assessed three different dosing regimens of litifilimab. The study highlighted significant improvements in skin disease activity when compared to the placebo group. These improvements were quantified using reductions in the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity scores.
Notably, the clinical responses to litifilimab were observed relatively quickly, setting it apart from traditional therapies such as hydroxychloroquine, which often require months to demonstrate effectiveness and may not work for a considerable number of patients.
All dosing groups in the trial exhibited benefits, reinforcing both the biological relevance of the therapeutic target and the potential of litifilimab as a treatment option. The rapidity and extent of the responses contributed significantly to the therapy’s recent designation by the FDA.
Patient-Centric Benefits of Improved CLASI Scores
Dr. Werth emphasized that enhancements in CLASI scores are directly correlated with substantial patient-centered benefits. Previous research has indicated that achieving a CLASI-50 (defined as a ≥50% improvement) correlates with notable enhancements in skin-specific quality of life metrics, such as those measured by the Skindex-29.
While higher response thresholds, such as CLASI-70, imply more rigorous disease control, they may not be essential for clinically meaningful improvements from the patient’s viewpoint. Current analyses are underway to better elucidate how various response levels align with functional and psychosocial outcomes in real-world settings.
Advancing to the Phase 3 AMETHYST Program
The upcoming phase 3 AMETHYST program builds upon the findings of the LILAC study. This program aims to evaluate a single, selected dose of litifilimab in a broader patient population over an extended period, with the goal of characterizing its efficacy and safety more definitively. This trial is designed to facilitate potential regulatory approval and expand patient access.
The Significance of FDA Breakthrough Therapy Designation
The FDA Breakthrough Therapy Designation is particularly significant in the context of cutaneous lupus erythematosus, a field that currently lacks therapies approved under modern regulatory frameworks. Dr. Werth stressed the importance of conducting dedicated trials for CLE, as existing medications approved for systemic lupus erythematosus are often not accessible to patients with primarily cutaneous manifestations of the disease.
This designation highlights the unmet medical needs in the field and recognizes litifilimab‘s promise in potentially enhancing patient outcomes in a condition that imposes considerable physical and psychosocial burdens. “Those of us who take care of patients with cutaneous lupus have been very excited to see the advances,” Dr. Werth concluded. “It is essential to conduct this type of study and to gain access to new therapies that will benefit patients.”
Sources
- Werth, V. et al. (2023). Phase 2 LILAC Study Results. The New England Journal of Medicine.
- FDA Breakthrough Therapy Designation Announcement. (2023). U.S. Food and Drug Administration.
- Skindex-29 Quality of Life Instrument. (2023). American Academy of Dermatology.